Clene Inc.
CLNNNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $200,000 | $342,000 | $654,000 | $473,000 | $723,000 | $206,000 |
| Operating income | −$23.1M | −$33.1M | −$40.5M | −$48.4M | −$50.0M | −$20.2M |
| Net income | −$26.2M | −$39.4M | −$49.5M | −$29.9M | −$9.7M | −$19.3M |
| Total assets | $18.1M | $27.3M | $52.3M | $44.5M | $63.1M | $68.2M |
| Total liabilities | $35.7M | $36.2M | $39.0M | $41.3M | $50.5M | $67.9M |
| Equity | −$17.6M | −$8.9M | $13.4M | $3.2M | $12.6M | $341,000 |
| EPS (diluted) | $-2.65 | $-5.67 | $-9.43 | $-0.46 | $-0.16 | — |
| Shares out. | 8.6M | 128.4M | 76.9M | 63.1M | 59.5M | 59.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −11541.5%
- Net margin
- −13086.5%
- Return on equity
- 148.8%
- Return on assets
- −144.4%
- Return on capital (ROCE)
- −313.8%
- Liabilities / assets
- 197.0%
- Debt / equity
- —
- Book value / share
- $-2.05
- Revenue growth (YoY)
- −41.5%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -65.16distress
- Accruals / assets
- −42.1%clean
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 5 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Ugwumba ChidoziePassive (13G)May 15, 2026
- Mosca AlisonPassive (13G)May 14, 2026
- Vivo Opportunity Fund Holdings, L.P.Passive (13G)May 12, 2026
- Awm Investment Company, Inc.Passive (13G)Nov 13, 2025
- 4life Research LlcPassive (13G)Feb 14, 2025
- Armistice Capital, LlcPassive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 1.3M | 1.0 | +51.2% |
| Apr 30, 2026 | 875,026 | 11.5 | -0.2% |
| Apr 15, 2026 | 876,909 | 11.2 | -9.8% |
| Mar 31, 2026 | 972,726 | 9.1 | +13.8% |
| Mar 13, 2026 | 855,132 | 14.4 | +1.3% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Director / officer change · Shareholder voteMay 22, 2026
- Entered a material agreement · Results of operationsMay 14, 2026
- Entered a material agreement · Other material eventMay 5, 2026
- Regulation FD disclosure · Other material eventMay 4, 2026
- Entered a material agreementMar 17, 2026
- Results of operationsMar 12, 2026
- Other material eventFeb 24, 2026
- Entered a material agreement · Other material eventJan 13, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SDFORM SDMay 22, 2026
- 8-KFORM 8-KMay 22, 2026
- 4FORM 4May 22, 2026
- 4FORM 4May 22, 2026
- 4FORM 4May 22, 2026
- 4FORM 4May 22, 2026
- 4FORM 4May 22, 2026
- 4FORM 4May 22, 2026
- 4FORM 4May 22, 2026
- 4FORM 4May 22, 2026
- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13G/AMay 14, 2026
- SCHEDULE 13G/AMay 14, 2026
- 8-KFORM 8-KMay 14, 2026
- 10-QFORM 10-QMay 14, 2026
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.